Published in final edited form as:

Ann Emerg Med. 2020 February ; 75(2): 147–158. doi:10.1016/j.annemergmed.2019.08.429.

Risk-stratification of Older Adults who Present to the Emergency Department with Syncope: The FAINT Score

Marc A. Probst, MD, MS¹, Thomas Gibson, BS², Robert E. Weiss, PhD², Annick N. Yagapen, MPH, CCRP³, Susan E. Malveau, MSBE³, David H. Adler, MD, MPH⁴, Aveh Bastani, MD⁵, Christopher W. Baugh, MD, MBA⁶, Jeffrey M. Caterino, MD, MPH⁷, Carol L. Clark, MD, MBA⁸, Deborah B. Diercks, MD, MPH⁹, Judd E. Hollander, MD¹⁰, Bret A. Nicks, MD, MHA¹¹, Daniel K. Nishijima, MD, MAS¹², Manish N. Shah, MD, MPH¹³, Kirk A. Stiffler, MD¹⁴, Alan B. Storrow, MD¹⁵, Scott T. Wilber, MD¹⁴, Benjamin C. Sun, MD, MPP¹⁶

¹Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

²Department of Biostatistics, University of California, Los Angeles, Los Angeles CA, USA

³Center for Policy and Research in Emergency Medicine, Department of Emergency Medicine, Oregon Health & Science University, Portland, OR, USA

⁴Department of Emergency Medicine, University of Rochester, Rochester, NY, USA

⁵Department of Emergency Medicine, William Beaumont Hospital-Troy, Troy, MI, USA

⁶Department of Emergency Medicine, Brigham & Women's Hospital, Boston, MA, USA

⁷Department of Emergency Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA

⁸Department of Emergency Medicine, William Beaumont Hospital-Royal Oak, Royal Oak, MI, USA

⁹Department of Emergency Medicine, University of Texas-Southwestern, Dallas, TX, USA, USA

¹⁰Department of Emergency Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA

Corresponding Author: Marc A. Probst, MD, MS, Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, 3 East 101st Street, Second Floor, Rm 218, New York, NY, 10029, USA, Telephone: 212-824-8094, Fax: 212-426-1946, mprobst@gmail.com.

Author Contributions Statement:

BCS and MAP designed the study. BCS obtained funding for this study. ANY and SEM were responsible for data collection and management. TG and REW provided statistical advice on study design and analyzed the data. MAP and BCS drafted the manuscript. All authors contributed substantially to manuscript revisions. BCS takes responsibility for the paper as a whole. BCS, TG, REW, ANY, and SEM had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors approved the final report for submission.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Clinical Trial Registration: Improving Syncope Risk Stratification in Older Adults. [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT01802398) Identifier: . <https://clinicaltrials.gov/ct2/show/NCT01802398>

Meetings: This study was presented as an oral abstract at the SAEM annual meeting in May of 2019 in Las Vegas, NV.

¹¹Department of Emergency Medicine, Wake Forest School of Medicine, Winston Salem, NC, USA

¹²Department of Emergency Medicine, UC Davis School of Medicine, Sacramento, CA, USA

¹³Department of Emergency Medicine, University of Wisconsin-Madison, Madison, WI, USA

¹⁴Department of Emergency Medicine, Northeastern Ohio Medical University, Rootstown, OH, USA

¹⁵Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

¹⁶Department of Emergency Medicine, University of Pennsylvania, Philadelphia, PA, USA

Abstract

Background: Older adults with syncope are commonly seen in the emergency department (ED). We sought to derive a novel risk-stratification tool to predict 30-day serious cardiac outcomes.

Methods: We performed a prospective, observational study of older adults (≥ 60 years) with unexplained syncope/near-syncope who presented to 11 EDs in the United States. Patients with a serious diagnosis identified in the ED were excluded. We collected clinical and laboratory data on all patients. Our primary outcome was 30-day all-cause mortality or serious cardiac outcome.

Results: We enrolled 3,177 older adults with unexplained syncope/near-syncope between April 2013 and September 2016. Mean age was 73 years (SD: 9.0 years). The incidence of the primary outcome was 5.7% (95% CI: 4.91-6.52%). Using Bayesian logistic regression, we derived the FAIN score: 1) history of heart Failure, 2) history of cardiac Arrhythmia, 3) Initial abnormal electrocardiogram, 4) elevated pro B-type Natriuretic peptide, and 5) elevated high-sensitivity Troponin T. A FAIN score of 0 vs. ≥ 1 had sensitivity of 96.7% (95% CI: 92.9, 98.8%) and specificity 22.2% (95% CI: 20.7, 23.8%), respectively. The FAIN score tended to be more accurate than unstructured physician judgment: area under the curve 0.704 (95% CI 0.669-0.739) vs 0.630, (95% CI 0.589-0.670).

Conclusions: Among older adults with syncope/near-syncope of potential cardiac etiology, a FAIN score of zero had a reasonably high sensitivity for excluding death and serious cardiac outcomes at 30 days. If externally validated, this tool could improve resource utilization for this common condition.

Introduction

Background

Emergency department (ED) visits for syncope (transient loss of consciousness) in the United States (US) are common¹ and increasing yearly², resulting in over \$2.4 billion in annual hospital costs.³ Due to the wide range of potential serious causes, particularly in older adults, the clinical management and disposition of these patients is often challenging.⁴

Importance

The quest for an accurate risk-stratification tool has been the “holy grail” of syncope research for the last two decades.^{5–14} Despite these efforts, significant uncertainty remains

regarding which patients with syncope can be safely discharged from the ED.^{7,15,16} None of the published risk-stratification rules have gained widespread adoption largely due to small sample sizes, failure of external validation, or lack of face validity.^{7,17–22} Moreover, these tools have not been compared with unstructured physician judgment¹⁶, a necessary comparison prior to investment in implementation efforts.²³

Roughly 30% of patients presenting to the ED with syncope are hospitalized;^{1,2} for older adults (>60 years), it is over 50%.²⁴ If a serious diagnosis is found in the ED, these patients may be hospitalized for specific therapeutic reasons (e.g., pacemaker insertion, blood transfusion). However, many older adults with syncope, despite having an unremarkable ED evaluation, are still admitted to inpatient or observation units solely for observation or further testing.^{2,25,26} These diagnostic admissions are costly³ and may be of little to no clinical benefit.^{27–30} An accurate, easy-to-use syncope risk-stratification tool focused on older adults could help decrease low-yield hospitalizations and diagnostic testing while maintaining patient safety.

Goals of This Investigation

Using a large sample size and Bayesian methodology, we sought to derive a novel clinical risk-stratification tool to predict 30-day all-cause mortality and serious cardiac outcomes in older adults with unexplained syncope/near-syncope of potential cardiac etiology. If externally validated in a new data set, such a tool could guide the ED clinical management and disposition of these patients to optimize resource use and improve clinical outcomes.

Methods

Study design and setting

We conducted a multicenter, prospective, observational study of older adults who presented to an ED with syncope or near-syncope ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier:). The study was conducted at 11 academic EDs, all located in not-for-profit hospitals, across the US (eTable 1), recruiting a diverse patient population, from April 28, 2013 to September 21, 2016. Ten out of 11 of the EDs were teaching hospitals with a trauma center; ED volume ranged from 47,000 to 120,000 visits per year. The institutional review boards at each site approved the study and study staff obtained written, informed consent from all participating subjects or their legally authorized representatives.

Selection of Participants

Our inclusion criteria were age ≥ 60 years with an ED complaint of syncope or near-syncope. Syncope was defined as transient loss of consciousness, associated with postural loss of tone, with immediate, spontaneous, and complete recovery. Near-syncope was defined as the sensation of impending loss of consciousness, without actual loss of consciousness. We excluded patients if their symptoms were thought to be due to intoxication, seizure, stroke, transient ischemic attack, head trauma, or hypoglycemia. Additional exclusion criteria were the need for medical intervention to restore consciousness (e.g., defibrillation), new or worsening confusion, and inability to obtain informed consent from the patient or a legally authorized representative.

For this analysis, we also excluded all patients who had a new serious diagnosis identified in the ED: death, significant cardiac arrhythmia, myocardial infarction, significant structural heart disease, stroke, pulmonary embolism, aortic dissection, hemorrhage or anemia requiring blood transfusion, subarachnoid hemorrhage, cardiopulmonary resuscitation, or major traumatic injury (eTable 2). We identified serious diagnoses via ED chart review performed by trained research assistants (RAs) and confirmed by the local physician site investigator.

Measurements

All patients underwent standardized history, physical examination, cardiac biomarker testing, and 12-lead electrocardiogram (ECG) testing. Any additional diagnostic testing was performed at the discretion of the treating providers, and availability of diagnostic testing was similar across sites. Trained RAs screened for eligible patients using standard definitions, approached potential subjects, collected data variables consistent with reporting guidelines for ED-based syncope research,³¹ and directly questioned patients about symptoms associated with the syncopal or near-syncopal episode. RAs prospectively collected data on the patient's past medical history, medications, and physical examination by querying treating ED providers. A sub-sample of data was collected a second time by another provider who blinded to the first evaluation to allow for assessment of inter-rater agreement using a kappa statistic.

Research staff obtained blood samples for testing at a core laboratory (University of Rochester, Rochester, NY). Two assays were performed using the Roche Elecsys platform: N-terminal pro B-type natriuretic peptide (NT-proBNP) and the 5th generation high-sensitivity cardiac troponin T, hs-cTnT. NT-proBNP was classified as abnormal above a cutoff of 125 pg/ml and hs-cTnT was classified as abnormal above the 99th percentile for a reference population i.e. 19 ng/L. Core laboratory results for NT-proBNP and hs-cTnT were not available at the time of the ED evaluation; however, the ED providers were free to order local BNP and troponin testing. We abstracted objective quantitative data, such as age, vital signs, and laboratory test results, from the electronic medical record. The first obtained ECG was abstracted by one of five research study physicians blinded to all clinical data. Research study physicians demonstrated high interrater reliability (kappa >0.80) in distinguishing normal from abnormal ECGs in a training set of 50 ECGs. Abnormal ECG interpretations included non-sinus rhythms (including paced rhythms), multiple premature ventricular complexes, sinus bradycardias (< 40 bpm), ventricular hypertrophies, short PR segment intervals (<100 ms), axis deviations, first degree blocks (>200 ms), complete bundle branch blocks, Brugada patterns, Wolff-Parkinson-White patterns, abnormal QRS duration (>120 ms) or abnormal QTc prolongations (>450 ms), and Q/ST/T segment abnormalities suggestive of acute or chronic ischemia. The disposition of the patients (admission vs. observation vs discharge) was decided by the treating providers per usual care.

In order to compare our final risk score to unaided physician gestalt,³² we also prospectively collected unstructured physician risk assessment by asking the treating ED attending to estimate the probability that the patient would experience cardiac death or serious cardiac event at 30 days (0-100%).

Outcomes

Our primary outcome was 30-day all-cause death or serious cardiac outcome. Serious cardiac outcomes included significant cardiac arrhythmia, myocardial infarction, new diagnosis of significant structural heart disease, or cardiac intervention. Significant cardiac arrhythmias included ventricular fibrillation, ventricular tachycardia, sick sinus disease, Mobitz II atrioventricular heart block, complete heart block, symptomatic supraventricular tachycardia, symptomatic bradycardia and pacemaker malfunction. Structural heart disease included aortic stenosis with valve area $\geq 1 \text{ cm}^2$, hypertrophic cardiomyopathy with outflow tract obstruction, severe pulmonary artery hypertension (mean arterial pressure $>30 \text{ mm Hg}$), left atrial myxoma or thrombus with protrusion and outflow tract obstruction. Cardiac interventions were defined as placement of a pacemaker or automated internal cardiac defibrillator, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or other invasive cardiac surgery. These outcomes are consistent with standardized research reporting and clinical management guidelines.^{15,31}

We determined occurrence of the primary outcome using data collected via a review of the electronic medical records conducted by local research staff, as well as telephone calls to enrolled patients at 30 days to identify out-of-hospital deaths, ED visits, and hospitalizations that occurred outside the study sites. To minimize outcome bias, RAs performing chart review were blinded to the clinical outcomes determined by telephone follow-up at 30 day. Multiple strategies were employed to maximize follow-up rates including patient incentives, electronic follow-up tracking, real-time confirmation of phone numbers, and continuing performance monitoring, as previously described.³³ If a patient or his or her authorized representative reported an ED or hospital visit that occurred outside of the study site, then we obtained and reviewed the medical charts associated with those visits. If research staff were unable to contact a patient at 30 days, we queried the Social Security Death Index Master File 16 months after enrollment completion.

To assess inter-rater reliability of chart review, records for the first five sequentially enrolled patients at each of the 10 external sites (excluding the coordinating center) were independently reviewed by local research staff and the coordinating center. The number of charts chosen (50) for this training set was limited by availability of research staff resources. All ten serious ED diagnoses and 30-days serious outcomes in the training set were identified by local site reviewers.

Predictors

We identified candidate predictors using a previously published systematic review and meta-analysis of the existing syncope risk-stratification literature.³⁴ We then performed a Bayesian meta-analysis allowing for the possibility of exact zero effects. We excluded variables that the Bayesian meta-analysis found to have little chance of being predictive of a serious cardiac outcome (e.g., co-occurring palpitations, history of stroke, syncope occurred while supine) and variables deemed irrelevant by expert physician judgment (e.g., Hispanic ethnicity). This left 13 variables: age, gender, hypotension, dyspnea, abnormal ECG, history of heart disease, history of arrhythmia, history of heart failure, low hematocrit ($<30\%$), elevated hs-cTnT, elevated NT-proBNP, elevated blood urea nitrogen, and elevated

creatinine. Further detail describing the selection of candidate predictors can be found in the statistical appendix.

Statistical Analysis

Using the 13 candidate variables as predictors, we fit a Bayesian logistic regression to the primary outcome variable. We choose to use a Bayesian approach over a conventional frequentist analysis since the former allows for the incorporation of previously reported empirical data pertaining to syncope risk-stratification.^{35,36} In particular, the Bayesian approach allowed us to incorporate both shrinkage and variable selection through choice of prior and also incorporated a component that performed multiple imputation of missing predictors. This model was fit to the entire data set. Complete details of the model are given in the statistical appendix. Inter-rater agreement was assessed using a kappa statistic with 95% confidence intervals (CIs) using normal approximation methods.

Five variables were identified as having a high probability of being predictive of a serious cardiac outcome. We fit the same Bayesian logistic model with selection/shrinkage priors and multiple imputation using just these five variables to ensure all five remained important in the absence of the excluded variables. With this final subset of five important variables, we performed Bayesian logistic regression with shrinkage but without model selection to obtain our final model.

We created the final syncope risk score by dividing posterior means of all regression coefficients by the smallest posterior mean and rounding to the nearest integer, as has been done for other health-related risk scores.³⁷ For each score cutoff we calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), with 95% CI using the exact binomial method. To account for overoptimism of the internal results we performed cross validation on the entire model selection and score creation procedure to get cross-validated estimates for sensitivity, specificity, PPV and NPV. A C-statistic, as well as positive and negative likelihood ratios were calculated for a risk score cutoff of zero. We assessed the calibration of the model by comparing the observed versus expected risk at each level of the score, as well as the Hosmer-Lemeshow goodness-of-fit statistic. We compared the predictive accuracy of the risk score with unstructured physician judgment using area under the receiving operator characteristic (ROC) curve with 95% CIs, as done in previous studies.^{38,39} Finally, we assessed the net reclassification improvement (NRI) statistic by comparing the performance of the final risk score to the disposition decision made by the treating physician. This was calculated by taking the percentage of correctly reclassified patients and subtracting the percentage of incorrectly reclassified patients. Correctly reclassified patients were defined as i) those who were risk score positive, had a serious outcome, and yet were discharged by the treating physician (i.e., inappropriate discharge), and ii) those who were risk score negative, had no serious outcome, and yet were admitted by the treating physician (i.e., unnecessary admit/observation unit stay). Incorrectly reclassified patients were defined as i) those who were risk score positive, had no serious outcome, and were discharged by the treating physician, and ii) those who were risk score negative, had a serious outcome, and were admitted by the treating physician.

Results

Characteristics of study subjects

Between April 2013 to September 2016, there were 6,930 eligible patients screened, of which 3,686 (53.2%) consented to participation in the study (See Figure 1). Of those consented, 396 were excluded from this analysis for a serious diagnosis found during the ED visit (10.7%), 103 (2.8%) were lost to follow-up and 10 (0.3%) were withdrawn leaving 3,177 with complete follow-up data at 30 days. The mean age of the study sample was 72.7 years (Standard Deviation [SD]: 8.97), 50.6% were male, and 82.9% reported white race. The majority of patients experienced syncope (n=1,965, 61.9%), while the remainder (38.1%) had near-syncope. Just over half (53.3%) had an abnormal initial ECG, and 29.3% had an elevated hs-cTnT. See Table 1 for further baseline characteristics.

At 30 days post-index ED visit, 180 (5.7%) patients experienced the primary outcome; 65 of these patients experienced an event after discharge. The most common outcome was a serious cardiac arrhythmia (n=94/180, 52.2%), of which symptomatic supraventricular tachycardia was the most common (n=35/180, 19.4%). Overall mortality at 30 days was 0.82% (26/3,177). Further data on 30-day serious outcomes are presented in Table 2. Missing data for predictor variables ranged from 0% to 7.6% for predictor variable (hs-cTnT 7.6%, NT-proBNP 4.9%, Dyspnea 2.2%). After multiple imputation, all 3,177 subjects were included in the analysis.

Main results

Our model selection process, using Bayesian logistic regression, resulted in five variables being significantly associated with the primary outcome: 1) history of heart failure, 2) history of cardiac arrhythmia, 3) abnormal initial electrocardiogram, 4) elevated NT-pro BNP, and 5) elevated hs-cTnT. The odds ratios (OR) and corresponding confidence intervals (CI) are presented in Table 3. These five variables make up the FAINT score (Failure, Arrhythmia, Initial ECG abnormal, abnormal Natriuretic peptide, abnormal high-sensitivity Troponin). The kappa statistic was good for all three of the non-numerical variables, heart failure: 0.70 (95%CI: 0.55 to 0.85), arrhythmia: 0.77 (95%CI: 0.66 to 0.87), and abnormal ECG: 0.65 (95%CI: 0.55 to 0.74). An older adult with unexplained syncope/near-syncope would be considered low-risk if none of the five FAINT variables are present during the ED evaluation, i.e. a FAINT score of zero. The sensitivity, specificity, positive and negative predictive values of a FAINT score of more than zero were 96.7%, 22.2%, 6.9%, and 99.1%, respectively (Table 4). The risk of death or serious cardiac outcome at 30 days for a patient with a FAINT score of zero was 0.9% (95% CI: 0.3, 1.9%) and 6.9% (95% CI: 6%, 8%) if greater than zero. The positive and negative likelihood ratios (LR) for a FAINT score of 1 or more were 1.24 (95%CI: 1.156, 1.336) and 0.15 (95%CI: 0.068, 0.329), respectively.

We modified the regression coefficients to obtain the point score associated with each variable, which resulted in point value of +2 for elevated NT-proBNP and +1 for all others. Total FAINT scores range from 0 to 6. Our model was well-calibrated demonstrating good agreement between observed and predicted risk at various score levels (See Figure 2a and

Figure 2b). Adequacy of calibration was confirmed by a non-significant Hosmer-Lemeshow goodness-of-fit statistic ($\chi^2 = 6.21$, 3 degrees of freedom, $p = 0.102$).

The test characteristics for each level of the FAIN score (0-6) are presented in Table 4. Results of our cross-validation are presented in eTable 3 and discussed in the statistical appendix (Section 5). The FAIN score had significantly better area under the curve (AUC) statistic (AUC = 0.704, 95% CI 0.669-0.739) compared to that of unstructured physician risk assessment (AUC = 0.630 95% CI 0.589-0.670), (DeLong's test for two correlated ROC curves, $Z=3.13$, $p=0.002$). The ROC curves are presented in Figure 3. Accounting for the optimism of internal validation, the cross-validated C-statistic of the FAIN score was 0.653 (95% CI: 0.534, 0.765). The total number of correctly reclassified patients was 466: 11 who were FAIN score positive, with a serious outcome, but discharged and 455 who were FAIN score negative, without a serious outcome, but were hospitalized by the treating physician. The total number of incorrectly reclassified patients was 456, 450 who were FAIN score positive, without a serious outcome and were discharged, and 6 who were FAIN score negative with a serious outcome, and were admitted by the treating physician. The percentage of correctly and incorrectly reclassified patients was 466/3,174 (14.68%) and 456/3,174 (14.37%), respectively, for a net reclassification improvement of 0.31% favoring the FAIN score (not significant $p=0.33$).

The FAIN score failed to predict the serious outcomes of 6 patients; these outcomes were: complete heart block leading to insertion of a pacemaker, structural heart disease, percutaneous transluminal coronary angioplasty, symptomatic bradycardia, sick sinus syndrome leading to the insertion of a pacemaker, and death. Conversely, the FAIN score would have identified 11 patients, which were not admitted to the hospital, as being high-risk; these outcomes were: 2 cases of symptomatic bradycardia, 2 cases of myocardial infarction, a case of ventricular tachycardia and coronary artery bypass graft, a pacemaker insertion, a coronary artery bypass graft, and four deaths (See eTable 4).

Limitations

Since we did not enroll patients <60 years old, the FAIN score was not designed to be applied to adults under this cut-off, which may limit its clinical utility. In light of the high patient refusal rate and low enrollment rate (53.2%), it is possible that sampling bias occurred. Our score requires the use of two assays that may not be readily available in all EDs (hs-cTnT and NT-proBNP), which may limit its use in such clinical settings. Our score would likely exhibit decreased sensitivity if used with a contemporary troponin assay. Our data apply only to the specific brand of these cardiac biomarkers (Roche Elecsys) and our result may not hold true when using other commercially available high-sensitivity troponin assays, (e.g. Abbott, Beckman, Siemens). These various assays have different limits of detection and imprecisions at the 99th percentile.⁴⁰ However, we do anticipate that high-sensitivity troponin assay will become increasingly common in the US in the coming years.^{41,42} Of note, substituting a conventional BNP assay for the NT-proBNP assay could be considered reasonable in EDs where only the former is available.^{43,44} Our composite primary outcome includes diagnoses with a wide range of severity, from atrial fibrillation to death. Clinicians should remember that certain diagnoses may be less serious and time-

sensitive than others when applying this score. While we did perform an internal cross-validation, an external validation was not within the scope of this project. We intend to pursue such a study in the future to validate this score in a distinct population of ED syncope patients. Although the specificity and positive LR of a FAIN score above zero are not markedly high, the purpose of this score is primarily to “rule-out” serious cardiac outcomes and was derived with this objective in mind. Clinicians should focus on the high sensitivity and low negative LR of this score.

Discussion

Using prospectively collected data from a large, multicenter sample of older adults presenting to the ED with syncope/near-syncope, we were able to derive an objective, 5-variable syncope risk score to predict the occurrence of serious cardiac outcomes at 30 days. This tool, if externally validated, could be used as a “one-way rule”⁴⁵ to guide clinical management for these patients by empowering clinicians to discharge low-risk patients (FAINT score =0) and consider further testing or observation for non-low-risk patients (FAINT score ≥ 1).

The FAIN score differs from previous syncope risk-stratification tools in the following five important ways. First, it was developed on the subset of syncope patients in which resource utilization is greatest, patients ≥ 60 years, whereas other tools have been developed on samples that include adolescents and adults of all ages.^{6,8–11} Adolescents and young adults (age <30 years) with syncope are at much lower risk for serious cardiac outcomes than middle-aged or older adults, and often have different etiologies of their syncope.^{15,25} Inclusion of younger adults in such a study sample would reduce the rate of serious outcomes; application of a syncope risk score to an inherently very low-risk cohort could lead to overtesting and false-positive screening. Second, our risk score incorporated novel cardiac biomarkers, i.e. NT-proBNP, hs-cTnT, both processed at a single, central laboratory, eliminating assay-to-assay variability. Although the hs-cTnT assay was not approved by the US Food and Drug Administration (FDA) at the time of study onset, we anticipated it would receive approval and eventually be integrated into clinical care (FDA granted approval in January 2017). Third, the components of our risk score are relatively simple and objective, i.e. does the patient have a history of heart failure or arrhythmia? Are the NT-proBNP or hs-cTnT levels elevated? These straightforward questions are less operator-dependent and more likely to show high inter-rater agreement than questions that require clinical gestalt.⁹ Fourth, our sample is one of the largest prospectively collected cohorts of ED syncope patients published, much larger than that used to derive prior risk-stratification tools.^{5,6,8,10} Fifth, our study set out to predict death and serious cardiac outcomes, and not *all* serious clinical outcomes, as other authors have done.^{6,8,9} We excluded non-cardiac outcomes a priori (e.g. ischemic stroke, subarachnoid hemorrhage, gastro-intestinal hemorrhage, aortic dissection, pulmonary embolism). Although the best definition of the primary outcome for a study of this nature is debatable, we believe that limiting the primary outcome to death and serious cardiac outcomes only is more suitable for the clinical scenario in question, i.e. unexplained syncope/near-syncope. There are already several risk-stratification tools currently available to predict the likelihood of pulmonary embolism,^{46,47} subarachnoid hemorrhage,^{48,49} aortic dissection,^{50,51} upper gastrointestinal hemorrhage,^{52,53} and ischemic stroke^{54,55}. The FAIN

score should be used only after these other diagnoses have been excluded during the initial ED evaluation, using clinical gestalt, relevant risk-stratification tools, or both, and potential cardiac etiologies remain. Moreover, the factors that predict cardiac arrhythmia, subarachnoid hemorrhage, occult gastrointestinal bleeding, and pulmonary embolism are like to be very different, as has been argued previously.¹⁶ Thus, a syncope risk score should predict serious *cardiac* outcomes and death, analogous to the HEART score for low risk chest pain.^{56,57}

As with any clinical decision rule that maximizes sensitivity, our corresponding specificity was less than desired. This creates the potential for application of the rule to paradoxically increase resource utilization if used in a “two-way” fashion, i.e. admitting all patients with a positive FAINT score.³² Thus, we caution clinicians to not use this rule prior to external validation, and, if validated, use it as a tool to justify the discharge of low-risk patients.

Our results add to the growing body of literature supporting the utility of BNP as a predictor of serious cardiac outcomes after an episode of syncope.^{6,58–63} An elevated NT-proBNP had an OR of 2.5, greater than that of any other clinical predictor we collected (Table 3). This suggests that a BNP assay should be strongly considered in the ED evaluation of older adults presenting with syncope or near-syncope. Given the score’s reliance on cardiac biomarkers, implementation could lead to an increase in laboratory testing, with a concomitant increase in costs, but could potentially lead to a decrease in admissions for unexplained syncope. A formal cost analysis would be required to determine the net effect.

Although the AUC for the FAINT score was modest (0.704), it did out-perform unstructured physician judgement (0.63), a statistically significant difference. The FAINT score did not result in a statistically significant improvement in correct reclassifications as compared to the physician’s disposition decision. The FAINT score did fail to predict a small number of serious clinical outcomes and the lower bound of the 95% CI was less than optimal. However, no risk-stratification tool should be used in isolation, but rather should be used to inform clinical decision-making while taking overall clinical gestalt and other non-clinical factors into account, e.g. social support of the patient, ability to obtain expedited follow-up care, values and preferences of the patient, and feasibility of returning to the ED promptly, to name a few. The FAINT score provides an objective, structured approach to risk-stratification that can be used by clinicians at all levels of skill and experience, which could reduce unwanted variation in the clinical management of syncope^{27,64,65}. The risk-stratification tool is meant to inform, not replace, clinical judgement, while potentially decreasing cognitive load for clinicians.

In summary, we used a large, multicenter, prospective dataset of older adults with syncope/near-syncope to derive a clinical risk score to identify patients at very low risk for death or serious cardiac outcomes at 30 days. Our score requires external validation prior to clinical implementation. If validated in a separate cohort of patients, the FAINT score has the potential to help guide clinical management by safely reducing low-yield hospitalizations.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments:

The authors would like to acknowledge the research assistants at all the study sites for their dedication to this project.

Grant Support:

Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R01HL111033. Dr. Probst is supported by a Career Development Award from the National Heart, Lung, and Blood Institute of the National Institutes of Health (K23HL132052). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Roche Diagnostics supplied high-sensitivity troponin-T assays. The sponsoring organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Conflicts of Interest: The authors have the following disclosures. MNS reports research funding from Roche and Omron, Inc. DHA has received research funding from Roche. AB has received research funding from Radiometer and Portola and has been a consultant for Portola. CWB has received advisory board and speaker's fees from Roche, research funding from Janssen and Boehringer Ingelheim, and consulting and advisory board fees from Janssen. JMC has received funding from Astra Zeneca. CLC has received research funding from Radiometer, Ortho Clinical Trials, Janssen, Pfizer, NIH, Portola, Biocryst, Glaxo Smith Klein, Hospital Quality Foundation, Astra Zeneca, and Abbott. CLC is also a consultant for Portola, Janssen, and Hospital Quality Foundation. DBD is a consultant for Janssen and Roche, has received institutional research support from Novartis, Ortho Scientific, and Roche, and is on the editorial board for Academic Emergency Medicine and Circulation. JEH has received research funding from Alere, Echosense, Siemens, Roche, Portola, and Trinity. DKN has received honorarium from Pfizer. ABS is a consultant for Siemens and Quidel and is on the Data and Safety Monitoring Board for Trevena. BCS is a consultant for Medtronic. The remaining authors have no financial disclosures.

References

1. Probst MA, Kanzaria HK, Gbedemah M, Richardson LD, Sun BC. National trends in resource utilization associated with ED visits for syncope. *Am J Emerg Med*. 2015;33(8):998–1001.4480060 [PubMed: 25943042]
2. Anderson TS, Thombley R, Dudley RA, Lin GA. Trends in Hospitalization, Readmission, and Diagnostic Testing of Patients Presenting to the Emergency Department With Syncope. *Ann Emerg Med*. 2018;72(5):523–532 [PubMed: 30342727]
3. Sun BC, Emond JA, Camargo CA Jr. Direct medical costs of syncope-related hospitalizations in the United States. *Am J Cardiol*. 2005;95(5):668–671 [PubMed: 15721118]
4. Kapoor WN. Evaluation and management of the patient with syncope. *JAMA*. 1992;268(18):2553–2560 [PubMed: 1404823]
5. Costantino G, Perego F, Dipaola F, et al. Short- and long-term prognosis of syncope, risk factors, and role of hospital admission: results from the STePS (Short-Term Prognosis of Syncope) study. *J Am Coll Cardiol*. 2008;51(3):276–283 [PubMed: 18206736]
6. Reed MJ, Newby DE, Coull AJ, Prescott RJ, Jacques KG, Gray AJ. The ROSE (risk stratification of syncope in the emergency department) study. *J Am Coll Cardiol*. 2010;55(8):713–721 [PubMed: 20170806]
7. Serrano LA, Hess EP, Bellolio MF, et al. Accuracy and quality of clinical decision rules for syncope in the emergency department: a systematic review and meta-analysis. *Ann Emerg Med*. 2010;56(4):362–373 e3612946941 [PubMed: 20868906]
8. Quinn JV, Stiell IG, McDermott DA, Sellers KL, Kohn MA, Wells GA. Derivation of the San Francisco Syncope Rule to predict patients with short-term serious outcomes. *Ann Emerg Med*. 2004;43(2):224–232 [PubMed: 14747812]

9. Thiruganasambandamoorthy V, Kwong K, Wells GA, et al. Development of the Canadian Syncope Risk Score to predict serious adverse events after emergency department assessment of syncope. *CMAJ*. 2016;188(12):E289–298.5008955 [PubMed: 27378464]
10. Colivicchi F, Ammirati F, Melina D, et al. Development and prospective validation of a risk stratification system for patients with syncope in the emergency department: the OESIL risk score. *Eur Heart J*. 2003;24(9):811–819 [PubMed: 12727148]
11. Grossman SA, Fischer C, Lipsitz LA, et al. Predicting adverse outcomes in syncope. *J Emerg Med*. 2007;33(3):233–239.2276584 [PubMed: 17976548]
12. Martin TP, Hanusa BH, Kapoor WN. Risk stratification of patients with syncope. *Ann Emerg Med*. 1997;29(4):459–466 [PubMed: 9095005]
13. Sun BC, Deroose SF, Liang LJ, et al. Predictors of 30-day serious events in older patients with syncope. *Ann Emerg Med*. 2009;54(6):769–778 e761–765.2788122 [PubMed: 19766355]
14. Del Rosso A, Ungar A, Maggi R, et al. Clinical predictors of cardiac syncope at initial evaluation in patients referred urgently to a general hospital: the EGSYS score. *Heart*. 2008;94(12):1620–1626 [PubMed: 18519550]
15. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2017;70(5):620–663 [PubMed: 28286222]
16. Sun BC, Costantino G, Barbic F, et al. Priorities for emergency department syncope research. *Ann Emerg Med*. 2014;64(6):649–655 e642 [PubMed: 24882667]
17. Birnbaum A, Esses D, Bijur P, Wollowitz A, Gallagher EJ. Failure to validate the San Francisco Syncope Rule in an independent emergency department population. *Ann Emerg Med*. 2008;52(2):151–159 [PubMed: 18282636]
18. Probst MA, Sun BC. How can we improve management of syncope in the Emergency Department? *Cardiol J*. 2014;21(6):643–650.5110209 [PubMed: 25299508]
19. Sun BC, Mangione CM, Merchant G, et al. External validation of the San Francisco Syncope Rule. *Ann Emerg Med*. 2007;49(4):420–427, 427 e421–424 [PubMed: 17210201]
20. Tan C, Sim TB, Thing SY. Validation of the San Francisco Syncope Rule in two hospital emergency departments in an Asian population. *Acad Emerg Med*. 2013;20(5):487–497 [PubMed: 23672363]
21. Thiruganasambandamoorthy V, Hess EP, Alreesi A, Perry JJ, Wells GA, Stiell IG. External validation of the San Francisco Syncope Rule in the Canadian setting. *Ann Emerg Med*. 2010;55(5):464–472 [PubMed: 19944489]
22. Reed MJ, Henderson SS, Newby DE, Gray AJ. One-year prognosis after syncope and the failure of the ROSE decision instrument to predict one-year adverse events. *Ann Emerg Med*. 2011;58(3):250–256 [PubMed: 21288597]
23. Schriger DL, Elder JW, Cooper RJ. Structured Clinical Decision Aids Are Seldom Compared With Subjective Physician Judgment, and Are Seldom Superior. *Ann Emerg Med*. 2017;70(3):338–344 e333 [PubMed: 28238497]
24. Sun BC, Emond JA, Camargo CA Jr. Characteristics and admission patterns of patients presenting with syncope to U.S. emergency departments, 1992–2000. *Acad Emerg Med*. 2004;11(10):1029–1034 [PubMed: 15466144]
25. Huff JS, Decker WW, Quinn JV, et al. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with syncope. *Ann Emerg Med*. 2007;49(4):431–444 [PubMed: 17371707]
26. Baugh CW, Liang LJ, Probst MA, Sun BC. National cost savings from observation unit management of syncope. *Acad Emerg Med*. 2015;22(8):934–941 [PubMed: 26204970]
27. Baugh CW, Sun BC, Syncope Risk Stratification Study G. Variation in diagnostic testing for older patients with syncope in the emergency department. *Am J Emerg Med*. 2018
28. Morag RM, Murdock LF, Khan ZA, Heller MJ, Brenner BE. Do patients with a negative Emergency Department evaluation for syncope require hospital admission? *J Emerg Med*. 2004;27(4):339–343 [PubMed: 15498613]

29. Shiyovich A, Munchak I, Zelingher J, Grosbard A, Katz A. Admission for syncope: evaluation, cost and prognosis according to etiology. *Isr Med Assoc J*. 2008;10(2):104–108 [PubMed: 18432020]
30. Canzoniero JV, Afshar E, Hedian H, Koch C, Morgan DJ. Unnecessary hospitalization and related harm for patients with low-risk syncope. *JAMA Intern Med*. 2015;175(6):1065–1067 [PubMed: 25894921]
31. Sun BC, Thiruganasambandamoorthy V, Cruz JD, Consortium to Standardize EDSRSR. Standardized reporting guidelines for emergency department syncope risk-stratification research. *Acad Emerg Med*. 2012;19(6):694–702.3376009 [PubMed: 22687184]
32. Green SM, Schriger DL, Yealy DM. Methodologic standards for interpreting clinical decision rules in emergency medicine: 2014 update. *Ann Emerg Med*. 2014;64(3):286–291 [PubMed: 24530108]
33. Nicks BA, Shah MN, Adler DH, et al. Minimizing Attrition for Multisite Emergency Care Research. *Acad Emerg Med*. 2017;24(4):458–466.5397346 [PubMed: 27859997]
34. Gibson TA, Weiss RE, Sun BC. Predictors of Short-Term Outcomes after Syncope: A Systematic Review and Meta-Analysis. *West J Emerg Med*. 2018;19(3):517–523. [PubMed: 29760850]
5942019 are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. No author has professional or financial relationships with any companies that are relevant to this study. There are no conflicts of interest or sources of funding to declare.
35. Weiss RE. Bayesian methods for data analysis. *Am J Ophthalmol*. 2010;149(2):187–188 e1812813219 [PubMed: 20103051]
36. Gurrin LC, Kurinczuk JJ, Burton PR. Bayesian statistics in medical research: an intuitive alternative to conventional data analysis. *J Eval Clin Pract*. 2000;6(2):193–204 [PubMed: 10970013]
37. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. *Stat Med*. 2004;23(10):1631–1660 [PubMed: 15122742]
38. Bandiera G, Stiell IG, Wells GA, et al. The Canadian C-spine rule performs better than unstructured physician judgment. *Ann Emerg Med*. 2003;42(3):395–402 [PubMed: 12944893]
39. Quinn JV, Stiell IG, McDermott DA, Kohn MA, Wells GA. The San Francisco Syncope Rule vs physician judgment and decision making. *Am J Emerg Med*. 2005;23(6):782–786 [PubMed: 16182988]
40. Apple FS, Collinson PO. Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays. *Clinical Chemistry*. 2012;58(1):54–61 [PubMed: 21965555]
41. Nowak RM, Gandolfo CM, Jacobsen G, et al. Ultrarapid Rule-out for Acute Myocardial Infarction Using the Generation 5 Cardiac Troponin T Assay: Results From the REACTION-US Study. *Ann Emerg Med*. 2018;72(6):654–664 [PubMed: 30119942]
42. Hollander JE. High-Sensitivity Troponin: Time to Implement. *Ann Emerg Med*. 2018;72(6):665–667 [PubMed: 30243545]
43. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. *Heart*. 2006;92(6):843–849.1860679 [PubMed: 16698841]
44. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. *Heart*. 2005;91(5):606–612.1768863 [PubMed: 15831643]
45. Rodriguez RM, Hendey GW. The Case for 1-Way Clinical Decision Rules in Emergency Medicine. *Ann Emerg Med*. 2015;66(6):689 [PubMed: 26590749]
46. Kline JA, Mitchell AM, Kabrheil C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. *J Thromb Haemost*. 2004;2(8):1247–1255 [PubMed: 15304025]
47. Wolf SJ, McCubbin TR, Feldhaus KM, Faragher JP, Adcock DM. Prospective validation of Wells Criteria in the evaluation of patients with suspected pulmonary embolism. *Ann Emerg Med*. 2004;44(5):503–510 [PubMed: 15520710]
48. Perry JJ, Sivilotti MLA, Sutherland J, et al. Validation of the Ottawa Subarachnoid Hemorrhage Rule in patients with acute headache. *CMAJ*. 2017;189(45):E1379–E1385. [PubMed: 29133539]

5687926 Lesiuk, Corinne Hohl, Marcel Emond, Lisa Calder, Christian Vaillancourt, Venkatesh Thiruganasambandamoorthy and Ian Stiell received grants from the Canadian Institutes of Health Research during the conduct of the study. Christian Vaillancourt also received a grant from the Heart and Stroke Foundation of Canada during the conduct of the study. No other competing interests were declared.

49. Perry JJ, Stiell IG, Sivilotti ML, et al. Clinical decision rules to rule out subarachnoid hemorrhage for acute headache. *JAMA*. 2013;310(12):1248–1255 [PubMed: 24065011]
50. Lovy AJ, Bellin E, Levsky JM, Esses D, Haramati LB. Preliminary development of a clinical decision rule for acute aortic syndromes. *Am J Emerg Med*. 2013;31(11):1546–1550.4275798 [PubMed: 24055476]
51. Nazerian P, Mueller C, Soeiro AM, et al. Diagnostic Accuracy of the Aortic Dissection Detection Risk Score Plus D-Dimer for Acute Aortic Syndromes: The ADVISED Prospective Multicenter Study. *Circulation*. 2018;137(3):250–258 [PubMed: 29030346]
52. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. *Lancet*. 2000;356(9238):1318–1321 [PubMed: 11073021]
53. Chen IC, Hung MS, Chiu TF, Chen JC, Hsiao CT. Risk scoring systems to predict need for clinical intervention for patients with nonvariceal upper gastrointestinal tract bleeding. *Am J Emerg Med*. 2007;25(7):774–779 [PubMed: 17870480]
54. Yang J, Fu JH, Chen XY, et al. Validation of the ABCD2 score to identify the patients with high risk of late stroke after a transient ischemic attack or minor ischemic stroke. *Stroke*. 2010;41(6):1298–1300 [PubMed: 20413737]
55. Purroy F, Jimenez Caballero PE, Gorospe A, et al. Prediction of early stroke recurrence in transient ischemic attack patients from the PROMAPA study: a comparison of prognostic risk scores. *Cerebrovasc Dis*. 2012;33(2):182–189 [PubMed: 22237056]
56. Backus BE, Six AJ, Kelder JC, et al. Chest pain in the emergency room: a multicenter validation of the HEART Score. *Crit Pathw Cardiol*. 2010;9(3):164–169 [PubMed: 20802272]
57. Laureano-Phillips J, Robinson RD, Aryal S, et al. HEART Score Risk Stratification of Low-Risk Chest Pain Patients in the Emergency Department: A Systematic Review and Meta-Analysis. *Ann Emerg Med*. 2019
58. Isbitan A, Hawatmeh A, Elnahar Y, et al. Utility of brain natriuretic peptide assay as a predictor of short term outcomes in patients presenting with syncope to the emergency department. *Cardiovasc Diagn Ther*. 2016;6(3):234–240.4880755 [PubMed: 27280086]
59. Tanimoto K, Yukiiri K, Mizushige K, et al. Usefulness of brain natriuretic peptide as a marker for separating cardiac and noncardiac causes of syncope. *Am J Cardiol*. 2004;93(2):228–230 [PubMed: 14715356]
60. Pfister R, Diedrichs H, Larbig R, Erdmann E, Schneider CA. NT-pro-BNP for differential diagnosis in patients with syncope. *Int J Cardiol*. 2009;133(1):51–54 [PubMed: 18237792]
61. Reed MJ, Newby DE, Coull AJ, Jacques KG, Prescott RJ, Gray AJ. Role of brain natriuretic peptide (BNP) in risk stratification of adult syncope. *Emerg Med J*. 2007;24(11):769–773.2658321 [PubMed: 17954830]
62. Costantino G, Solbiati M, Casazza G, et al. Usefulness of N-terminal pro-B-type natriuretic Peptide increase as a marker for cardiac arrhythmia in patients with syncope. *Am J Cardiol*. 2014;113(1):98–102 [PubMed: 24169011]
63. Thiruganasambandamoorthy V, Ramaekers R, Rahman MO, et al. Prognostic value of cardiac biomarkers in the risk stratification of syncope: a systematic review. *Intern Emerg Med*. 2015;10(8):1003–1014 [PubMed: 26498335]
64. Thiruganasambandamoorthy V, Taljaard M, Stiell IG, et al. Emergency department management of syncope: need for standardization and improved risk stratification. *Intern Emerg Med*. 2015;10(5):619–627 [PubMed: 25918108]
65. Costantino G, Sun BC, Barbic F, et al. Syncope clinical management in the emergency department: a consensus from the first international workshop on syncope risk stratification in the emergency department. *Eur Heart J*. 2016;37(19):1493–1498.4872282 [PubMed: 26242712]

Figure 1:
Patient Flow Diagram

Figure 2a and 2b:
Observed vs Predicted Risk Plot

Figure 3. Comparison of the ROC Curves for the FAINT score vs. Physician Risk Assessment
ROC: Receiver Operating Characteristic.

Table 1:
Characteristics of Older Adults Presenting to the ED with Syncope or Near-Syncope

Variable	Overall (N=3,177)	With Serious Outcome at 30 days(n=180)	No Serious Outcome at 30 days (n=2,997)	Missing Data
Age				0 (0.0%)
Mean (SD)	72.74 (8.97)	73.52 (9.14)	72.69 (8.96)	
Age Category (n, %)				0 (0.0%)
60 to <70	1384 (43.6)	70 (38.9)	1314 (43.8)	
70 to <80	1013 (31.9)	61 (33.9)	952 (31.8)	
80 to <90	643 (20.2)	39 (21.7)	604 (20.2)	
90+	137 (4.3)	10 (5.6)	127 (4.2)	
Gender				
Male	1608 (50.6)	103 (57.2)	1505 (50.2)	
Race				19 (0.6%)
White or Caucasian	2618 (82.9)	151 (83.9)	2467 (82.8)	
Black or African American	442 (14.0)	25 (13.9)	417 (14.0)	
Other	98 (3.1)	4 (2.2)	94 (3.2)	
Near-syncope	1,212 (38.1)	67 (37.2)	1,145 (38.2)	
Syncope	1,965 (61.9)	113 (62.8)	1,852 (61.8)	
History of:				
Congestive Heart Failure	376 (11.8)	45 (25.0)	331 (11.1)	3 (0.1%)
Coronary Artery Disease	847 (26.7)	68 (37.8)	779 (26.0)	3 (0.1%)
Arrhythmia	630 (19.8)	63 (35.0)	567 (18.9)	3 (0.1%)
Dyspnea	617 (19.9)	44 (25.3)	573 (19.5)	71 (2.2%)
Chest discomfort	268 (8.4)	20 (11.1)	248 (8.3)	0 (0.0%)
Hypotension	313 (9.9)	26 (14.5)	287 (9.6)	20 (0.6%)
Abnormal ECG	1665 (53.3)	128 (72.7)	1537 (52.1)	51 (1.6)
Physician Risk Assessment, mean (SD)	5.00 [2.00, 10.00]	8.00 [5.00, 15.00]	5.00 [2.00, 10.00]	90 (2.8%)
Cardiac Biomarkers				
NT-proBNP > 125 pg/ml	1928 (63.8)	152 (87.4)	1776 (62.4)	156 (4.9%)
NT-proBNP, median [IQR]	213.00 [82.00, 661.00]	874.00 [227.50, 1846.50]	200.00 [80.00, 597.00]	
Hs-Troponin T > 19 ng/L	863 (29.4)	90 (53.3)	773 (27.9)	240 (7.6%)
Hs-Troponin T, median [IQR]	11.00 [6.00, 22.00]	21.00 [11.00, 41.00]	11.00 [6.00, 21.00]	

ECG: Electrocardiogram; SD: Standard Deviation; NT-proBNP: N-terminal pro B-type natriuretic peptide; hs: high-sensitivity; IQR: Interquartile Range.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2:

All-cause Death and Serious Cardiac Outcomes at 30 days

	Overall	Post-discharge	In hospital
Any 30-day serious outcome	180	56	124 [*]
30-day death	26	24	2
<u>Serious Cardiac Arrhythmias:</u>			
Any cardiac arrhythmia	94	24	70
Ventricular fibrillation	3	1	2
Ventricular tachycardia (>30 secs)	10	2	8
Symptomatic ventricular tachycardia (<30 secs)	3	1	2
Sick sinus disease with alternating sinus bradycardia and tachycardia	14	3	11
Sinus Pause >3 seconds	4	0	4
Mobitz II atrioventricular heart block	5	3	2
Complete heart block	8	2	6
Symptomatic supraventricular tachycardia	35	9	26
Symptomatic bradycardia	11	3	8
Pacemaker or AICD malfunction with cardiac pauses	1	0	1
<u>Cardiac Intervention:</u>			
Any cardiac intervention	74	22	52
Pacemaker	36	10	26
AICD	9	2	7
CABG	8	4	4
PTCA	11	4	7
Other	10	2	8
<u>Other Serious Outcomes:</u>			
Myocardial infarction	24	9	15
New diagnosis of structural heart disease	26	3	23

* Nine patients had events both in hospital and post-discharge; these were counted in the "in hospital" column.

AICD: Automated Implantable Cardioverter-Defibrillator. CABG: Coronary Artery Bypass Graft. PTCA: Percutaneous Transluminal Coronary Angioplasty.

Table 3:

Results of Bayesian Logistic Regression (FAINT score)

Predictor	Point Score	Odds Ratio	95% CI
F: History of Heart Failure	+1	1.585	(1.091, 2.269)
A: History of Arrhythmia	+1	1.549	(1.103, 2.143)
I: Initial ECG Abnormal	+1	1.578	(1.114, 2.263)
N: NT-proBNP	+2	2.535	(1.581, 4.131)
T: Hs-Troponin T	+1	1.853	(1.323, 2.587)

ECG: electrocardiogram; hs: high-sensitivity; NT-proBNP: N-terminal pro B-type natriuretic peptide; CI: Confidence Interval.

Test Characteristics of the FAINTE Score to Predict Serious Clinical Outcomes at 30 days

Table 4:

Score	No. Patients	No. Bad Outcomes	Estimated Risk	Sensitivity	Specificity	PPV	NPV
0	672	6	0.9%	NA	NA	NA	NA
1	447	14	3.1%	0.967 (0.929, 0.988)	0.222 (0.207, 0.238)	0.069 (0.060, 0.080)	0.991 (0.981, 0.997)
2	499	18	3.6%	0.889 (0.834, 0.931)	0.367 (0.349, 0.384)	0.078 (0.067, 0.090)	0.982 (0.973, 0.989)
3	684	45	6.6%	0.789 (0.722, 0.846)	0.527 (0.509, 0.545)	0.091 (0.077, 0.106)	0.977 (0.968, 0.983)
4	561	59	10.5%	0.539 (0.463, 0.613)	0.740 (0.724, 0.756)	0.111 (0.091, 0.134)	0.964 (0.955, 0.971)
5	235	19	8.1%	0.211 (0.154, 0.278)	0.908 (0.897, 0.918)	0.121 (0.087, 0.162)	0.950 (0.942, 0.958)
6	79	19	24.1%	0.106 (0.065, 0.160)	0.980 (0.974, 0.985)	0.241 (0.151, 0.350)	0.948 (0.940, 0.956)
Total:	3177	180					

PPV: positive predictive value, NPV: negative predictive value.

* Sensitivity/Specificity/PPV/NPV calculated by defining "at risk" as having that score or above (e.g. score ≥ 1 gives sensitivity=0.967)